Cell type |
IL-21 actions |
References |
Th17 cells |
IL-21 is an autocrine cytokine for Th17 differentiation and up-regulates IL-23R expression to maintain Th17 cell phenotype |
[20,28,29] |
TFH cells |
Facilitates TFH differentiation; IL-21 is a major effector cytokine of TFH |
[30-32] |
Th1, Th2 cells |
Inhibits IFN-γ but increases other Th1 molecules; IL-21 can be produced by Th1 and Th2 cells |
[2] |
Treg cells |
Counteracts Treg suppression by acting on conventional T cells |
[62] |
CD8 T cells |
Up-regulates proliferation and effector function; Sustains effector function during antigen persistence |
[2-5] |
B cells |
Promotes B cell proliferation, plasma cell differentiation, IgG production, GC formation; Inhibits IgE production by inducing apoptosis of IgE-expressing B cells |
[35-39] |
DCs |
IL-21R is required for antigen transport by DCs |
[63] |
NKT cells |
Enhances survival, proliferation, granzyme B expression, cytokine production; NKT cells also produce IL-21 |
[12,13] |
Murine model |
|
|
Infection |
Controls chronic viral infection by sustaining CD8 T cell function |
[3-5] |
SLE |
Mice with SLE produce high levels of IL-21; IL-21R deficiency or IL-21R.Fc treatment inhibits B cell-mediated lupus pathology |
[18,40,41] |
T1D |
IL-21 over-expression in pancreatic β cells induces T1D in C57Bl/6 mice; IL-21 or IL-21R deficiency prevents T1D onset in NOD mice; IL-21R.Fc treatment prolongs islet graft survival; CCR9+ Th cells in the pancreas produce IL-21; IL-21 signal controls DC-mediated antigen transport |
[6,7,9,34,63] |
IBD |
IL-21 deficient mice are protected against colitis |
[64] |
RA |
IL-21R deficient K/BxN mice inhibited the development of arthritis |
[65] |
EAE |
IL-21 or IL-21R deficiency does not prevent MOG-induced EAE |
[43,44] |
Tumor |
IL-21 monotherapy inhibits tumor growth in various models |
[66] |
Human disease |
|
|
Autoimmunity |
Polymorphisms in IL-21 or IL-21R genes associate with SLE, T1D, IBD, and RA; Elevated expression of IL-21 or IL-21R was found in patients with SLE, IBD, and RA |
[66-69] |
Tumor |
Recombinant IL-21 is undergoing Phase I and II testing for treatment of metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma |
[70] |